A Concise Workup of COPD E. James Britt, MD
description
Transcript of A Concise Workup of COPD E. James Britt, MD
![Page 1: A Concise Workup of COPD E. James Britt, MD](https://reader030.fdocuments.us/reader030/viewer/2022013012/56816865550346895ddec277/html5/thumbnails/1.jpg)
A Concise Workup of COPDE. James Britt, MD
Common diseases are common3rd leading cause of mortality
COPD is overlookedWomen > men but underdiagnosed
Core w/u is simpleWe will quickly outline an office evalWe will review goals of therapy, and how and what goals can be met today
![Page 2: A Concise Workup of COPD E. James Britt, MD](https://reader030.fdocuments.us/reader030/viewer/2022013012/56816865550346895ddec277/html5/thumbnails/2.jpg)
![Page 3: A Concise Workup of COPD E. James Britt, MD](https://reader030.fdocuments.us/reader030/viewer/2022013012/56816865550346895ddec277/html5/thumbnails/3.jpg)
![Page 4: A Concise Workup of COPD E. James Britt, MD](https://reader030.fdocuments.us/reader030/viewer/2022013012/56816865550346895ddec277/html5/thumbnails/4.jpg)
![Page 5: A Concise Workup of COPD E. James Britt, MD](https://reader030.fdocuments.us/reader030/viewer/2022013012/56816865550346895ddec277/html5/thumbnails/5.jpg)
Natural History of COPD(Fletcher and Peto)
* Death due to irreversible chronic obstructive lung disease.* Death due to irreversible chronic obstructive lung disease.Reprinted with Reprinted with permission from Fletcher C, Peto R. The natural history of chronic airflow permission from Fletcher C, Peto R. The natural history of chronic airflow obstruction. obstruction. Br Med J. Br Med J. 1977;1(6077):1645-16481977;1(6077):1645-1648
0
25
50
75
100
25 50 75
Forced Forced Expiratory Expiratory Volume inVolume in1 Second 1 Second
(FEV(FEV11))[% of Value [% of Value at Age 25]at Age 25]
DisabilityDisability
DeathDeath
Age (Years)Age (Years)
Never smoked Never smoked or not or not susceptible to susceptible to smokesmoke
Smoke regularly Smoke regularly and susceptible and susceptible to its effectsto its effects Stopped at age 45Stopped at age 45
Stopped at age 65Stopped at age 65
** **
![Page 6: A Concise Workup of COPD E. James Britt, MD](https://reader030.fdocuments.us/reader030/viewer/2022013012/56816865550346895ddec277/html5/thumbnails/6.jpg)
0
10
20
30
40
50
60
70
1980 1985 1990 1995 2000
Men Women
COPD Mortality in the United StatesNot What You Would Suspect?
1980-2000
YearYear
Abs
olut
e N
o. D
eath
s A
bsol
ute
No.
Dea
ths
per 1
00,0
00pe
r 100
,000
Mannino et al. Mannino et al. MMWR Morb Mortal Wkly Rep.MMWR Morb Mortal Wkly Rep. 2002;51(SS-6):1-16. 2002;51(SS-6):1-16.
![Page 7: A Concise Workup of COPD E. James Britt, MD](https://reader030.fdocuments.us/reader030/viewer/2022013012/56816865550346895ddec277/html5/thumbnails/7.jpg)
Questioning a patient thought to have COPDCough, SOB, Chest Pain
• Smoker?• Childhood allergies, asthma?• SOB:
– House/apartment, 1-3 floors?– Up/down at will; once daily; ask others?– Yard work, laundry, mail,daily errands, trapped?– Arm work?– Nocturnal attacks?
• Hospital or ER?• Medication Review
![Page 8: A Concise Workup of COPD E. James Britt, MD](https://reader030.fdocuments.us/reader030/viewer/2022013012/56816865550346895ddec277/html5/thumbnails/8.jpg)
Criteria for Diagnosis of COPD• Clinical history
– Exposure: smoke, other– Symptoms: cough, sputum, dyspnea
• Functional assessment– Spirometry (FEV1, forced vital capacity [FVC], and FEV1/FVC ratio)– Oxygenation– Lung volumes– Diffusion capacity
• Anatomic assessment– Chest x-ray– High resolution CT scan
Pauwels RA, et al, on behalf of the GOLD Scientific Committee. Pauwels RA, et al, on behalf of the GOLD Scientific Committee. Am J Respir Crit Care Med.Am J Respir Crit Care Med. 2001;163:1256-1276.2001;163:1256-1276.
![Page 9: A Concise Workup of COPD E. James Britt, MD](https://reader030.fdocuments.us/reader030/viewer/2022013012/56816865550346895ddec277/html5/thumbnails/9.jpg)
Prognosis of Airways Obstruction in Tuscon >age 65
![Page 10: A Concise Workup of COPD E. James Britt, MD](https://reader030.fdocuments.us/reader030/viewer/2022013012/56816865550346895ddec277/html5/thumbnails/10.jpg)
Pharmacologic RX of COPD
• Short Acting Bronchodilators• Long Acting Maintanance Drugs• Supplemental Medications• Meds to Rx Exacerbations• Meds to Prevent Exacerbations• Medications to Preserve Lung Function• Medications to Reduce Mortality
![Page 11: A Concise Workup of COPD E. James Britt, MD](https://reader030.fdocuments.us/reader030/viewer/2022013012/56816865550346895ddec277/html5/thumbnails/11.jpg)
Short Acting Bronchodilators
• Beta Agonist Family– Pro Air; Proventil; Ventolin; Albuterol;
Xopinex $40-$45• Anticholinergic Family
– Atrovent,• Combination
– Combivent; Respimat $210
![Page 12: A Concise Workup of COPD E. James Britt, MD](https://reader030.fdocuments.us/reader030/viewer/2022013012/56816865550346895ddec277/html5/thumbnails/12.jpg)
Long Acting Bronchodilators
• Anticholinergics– Tiotropium; Aclidinium $250
• Beta AgonistsSalmeterol, Formoterol, Indacaterol $250
• Steroid/Beta Agonist Combinations– Advair 250/50; Salmeterol 160/4.5 $250
![Page 13: A Concise Workup of COPD E. James Britt, MD](https://reader030.fdocuments.us/reader030/viewer/2022013012/56816865550346895ddec277/html5/thumbnails/13.jpg)
Supplemental Medications
• Theophylline
![Page 14: A Concise Workup of COPD E. James Britt, MD](https://reader030.fdocuments.us/reader030/viewer/2022013012/56816865550346895ddec277/html5/thumbnails/14.jpg)
Theophylline1
• If response to initial anticholinergic/2-agonist therapy suboptimal, consider adding theophylline
• Long-acting formulations generally preferred– Modest bronchodilation, mild anti-inflammatory effects
• Useful for noncompliant patients and those who have trouble with inhalation aerosols and those preferring oral drugs
1. NCAP. J Respir Dis. 2000;21(suppl):S5-S21.
![Page 15: A Concise Workup of COPD E. James Britt, MD](https://reader030.fdocuments.us/reader030/viewer/2022013012/56816865550346895ddec277/html5/thumbnails/15.jpg)
Medications to Prevent Exacerbations
• Rofumulast $300• Azithromycin
![Page 16: A Concise Workup of COPD E. James Britt, MD](https://reader030.fdocuments.us/reader030/viewer/2022013012/56816865550346895ddec277/html5/thumbnails/16.jpg)
PD4 Inhibitors-Roflumilast• Six and Twelve month data document decreased
exacerbations in a COPD cohort with recurrent exacerbations of chronic bronchitis and use of inhalled glucorticoids
• Limited by headache, nausea, diarrhea and weight loss
• **Never gone head-head against theophylline• Many in pipeline…special interest in inhalled
![Page 17: A Concise Workup of COPD E. James Britt, MD](https://reader030.fdocuments.us/reader030/viewer/2022013012/56816865550346895ddec277/html5/thumbnails/17.jpg)
Azithromycin and COPD
• COPD consortium: UMMD/Scharf (Albert)• 250 mg AZ/d 570 patients• Time to Exacerbation extended by 92 days
– Placebo=174d Az=266d– Risk Rate
• Placebo=1.83/yr Az=1.48/yr
• Limited by ototoxicity, cardiac toxicity, drug-drug toxicity
![Page 18: A Concise Workup of COPD E. James Britt, MD](https://reader030.fdocuments.us/reader030/viewer/2022013012/56816865550346895ddec277/html5/thumbnails/18.jpg)
Recommendation for Azithromycin Use in COPD
• >= 2 exacerbation/yr• Compliant patient• Pulse <100• QT<450 msec.• SGOT/SGPT < 3X normal• No QT drugs• Hearing OK, Audiogram ?• Exclude high cardiac risk patient
![Page 19: A Concise Workup of COPD E. James Britt, MD](https://reader030.fdocuments.us/reader030/viewer/2022013012/56816865550346895ddec277/html5/thumbnails/19.jpg)
Principal of Mix & MatchCombination therapy
• My role here is that of a shopping assistant really recommending ways in which a patient may mix and match medications to achieve goals…challenging given the $$ involved
![Page 20: A Concise Workup of COPD E. James Britt, MD](https://reader030.fdocuments.us/reader030/viewer/2022013012/56816865550346895ddec277/html5/thumbnails/20.jpg)
Escalating Menu of ChoicesA moderate to severe patient
• Long acting anticholinergic $260• Steroid/Long act beta agonist $250• Long acting beta agonist $120• Short acting rescue drug $ 50• Preventitave drug $300
![Page 21: A Concise Workup of COPD E. James Britt, MD](https://reader030.fdocuments.us/reader030/viewer/2022013012/56816865550346895ddec277/html5/thumbnails/21.jpg)
Prevention of Relapse
• Tiotropium and two Steroid/beta agonist maintanance inhalers have secondary endpoint claims from large long-term studies.
• Additional preventative strategies were reviewed
![Page 22: A Concise Workup of COPD E. James Britt, MD](https://reader030.fdocuments.us/reader030/viewer/2022013012/56816865550346895ddec277/html5/thumbnails/22.jpg)
Preservation of Lung function
• No major studies document preservation of lung function at this time. It remains the elusive goal.
![Page 23: A Concise Workup of COPD E. James Britt, MD](https://reader030.fdocuments.us/reader030/viewer/2022013012/56816865550346895ddec277/html5/thumbnails/23.jpg)
Statins
• Observations– Diminished decline in PFT– Decreased ER & H documented
• COPD Consortium: STATSCOPE– 3 yr 1000 participants– ? Direct effect on COPD– ? Indirect benefit thru heart disease
![Page 24: A Concise Workup of COPD E. James Britt, MD](https://reader030.fdocuments.us/reader030/viewer/2022013012/56816865550346895ddec277/html5/thumbnails/24.jpg)
Improve exercise performance
• Both long acting anticholinergics and long acting beta agonists have data that show increased esercise time and or endurance oner two months of regular use likely thru the lung volume reduction effect
![Page 25: A Concise Workup of COPD E. James Britt, MD](https://reader030.fdocuments.us/reader030/viewer/2022013012/56816865550346895ddec277/html5/thumbnails/25.jpg)
Days
400
500
600
700
-5 0 5 10 15 20 25 30 35 40 45
Exer
cise
dur
atio
n (s
econ
ds)
491.7 sec
+ 105.2 sec + 21.4 %+ 66.8 sec
+ 13.6 %
** p<0.01
* p<0.05
***
Tiotropium Exercise Trial: Endurance Time Tiotropium Exercise Trial: Endurance Time During Constant Work ExerciseDuring Constant Work Exercise
Tiotropium (n=96)Placebo (n=91)
BaselineO’Donnell et all ERJ 2004 (in press).
![Page 26: A Concise Workup of COPD E. James Britt, MD](https://reader030.fdocuments.us/reader030/viewer/2022013012/56816865550346895ddec277/html5/thumbnails/26.jpg)
![Page 27: A Concise Workup of COPD E. James Britt, MD](https://reader030.fdocuments.us/reader030/viewer/2022013012/56816865550346895ddec277/html5/thumbnails/27.jpg)
ACP Clinical Practice GuidelinesCOPD
Spirometry to dx airflow obstruction, but not to screen• Stable FEV1 60-80% bronchodilators MAY be used• Stable FEV1 <60% monotherapy with long act bd• FEV1<60% Rx LAMA or LABA patient pref, cost,
adverse event profile• May adm combination rx for symptomatic pts• Rehab for <50% FEV1• O2 for resting hypoxemia, usual guidelines
![Page 28: A Concise Workup of COPD E. James Britt, MD](https://reader030.fdocuments.us/reader030/viewer/2022013012/56816865550346895ddec277/html5/thumbnails/28.jpg)
![Page 29: A Concise Workup of COPD E. James Britt, MD](https://reader030.fdocuments.us/reader030/viewer/2022013012/56816865550346895ddec277/html5/thumbnails/29.jpg)